CGBIO announced on Thursday its participation in the IMCAS World Congress 2026, a prestigious cosmetic surgery conference held in Paris, France.
The event, which took place from January 29 to 31 at the Palais des Congrès de Paris, drew over 20,000 medical professionals and industry representatives from 136 countries, along with approximately 400 companies.
At its exhibition booth, CGBIO showcased its innovative collagen stimulator, Facetem, as well as its hyaluronic acid (HA) based fillers, AiLEENE and Giselleligne.
The company also conducted a clinical education program for global medical professionals during the event, focusing on its cutting-edge aesthetic products.
Through this high-profile event, CGBIO secured global contracts totaling 101.5 billion KRW (about 70.4 million USD).
The company renewed its supply agreement with its Brazilian distributor for AiLEENE and Facetem, striking a deal worth 58.7 billion KRW (about 40.7 million USD) over the next five years.
Additionally, CGBIO inked a new five-year supply contract for Facetem with its Canadian distributor, valued at 7.5 billion KRW (about 5.2 million USD).
The company also confirmed contracts and new orders worth 15.3 billion KRW (about 10.6 million USD) with distributors in China and Latin American countries, including Argentina, Colombia, and Uruguay.
Chief Executive Officer (CEO) Yoo Hyun-seung stated that they’re committed to further strengthening CGBIO’s position in the global aesthetic market through evidence-based education and expanded international partnerships.